in vitro News and Research

RSS

Cleavage stage embryo with aneuploidy can undergo genetic normalisation process

Professor William G. Kearns told the annual meeting of the European Society of Human Reproduction and Embryology that a three-day-old embryo with an incorrect number of chromosomes was capable of undergoing "a dynamic process of genetic normalisation" so that by day five, when it had developed to the blastocyst stage, it had become euploid, with the correct number of chromosomes.

5 Jul 2011

New insight into oocyte chromosome abnormalities

Ovarian stimulation undertaken by women of advanced maternal age receiving fertility treatment may be disrupting the normal pattern of meiosis - a critical process of chromosome duplication followed by two specialised cell divisions in the production of oocytes and sperm - and leading to abnormalities of chromosome copy numbers that result in IVF failure, pregnancy loss or, more rarely, the birth of affected children with conditions such as Down's syndrome, which is caused by the inheritance of three copies of chromosome 21.

4 Jul 2011

Researchers use clever technique to look at in vivo virus-bacterium interactions

Viruses are the most abundant parasites on Earth. Well known viruses, such as the flu virus, attack human hosts, while viruses such as the tobacco mosaic virus infect plant hosts.

2 Jul 2011

Study about U.S. attitudes toward human embryonic stem cell research

While research using human embryonic stem cells has roused political controversy for almost two decades, little has been done to scientifically assess American attitudes on the subject. New research from the University of Nevada, Reno provides decision-makers with a much clearer picture of how their constituents truly feel about the subject.

30 Jun 2011

IOTA NanoSolutions secures funding for commercialisation of ContraSol technology

IOTA NanoSolutions Limited, a specialist formulation company, is pleased to announce today that it has completed a financing round to support the commercialisation of its proprietary nanodispersion formation technology, ContraSol™. New investor, QIB(UK) Plc joins Unilever Ventures Limited (UV) in this financing round.

28 Jun 2011

AMRI, Proteros ink new partnership

AMRI and Proteros Biostructures GmbH announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

28 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

Leaky blood vessels may cause sepsis rather than a symptom: Research

Researchers at St. Michael's Hospital have put forward a new theory as to what causes sepsis, an often fatal condition that occurs when infection spreads throughout the body.

24 Jun 2011

Adding leucine to diets improves insulin sensitivity, pre-diabetic condition and metabolic syndrome

A study led by researchers at the Joslin Diabetes Center suggests that adding the amino acid leucine to their diets may help those with pre-diabetes or metabolic syndrome.

23 Jun 2011

VENENUM opens new medicinal chemistry facility in Hamilton, NJ

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify potential therapeutic agents against its novel disease-based targets, or its partners' targets, announced today that it opened its new medicinal chemistry space at 8 Black Forest Road in Hamilton, NJ.

22 Jun 2011

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.

22 Jun 2011

Reduced levels of VAPB protein may play central role in causing ALS

An international team of scientists led by researchers at the University of California, San Diego School of Medicine have used induced pluripotent stem cells (iPSCs) derived from patients with amyotrophic lateral sclerosis (ALS) to reveal for the first time how reduced levels of a specific protein may play a central role in causing at least one inherited form of the disease.

22 Jun 2011

New technique makes artificial bones more natural

A new technique for producing artificial bone implants has been developed by Korean researchers. Published in the journal Science and Technology of Advanced Material (STAM), the technique combines two methods to approximate both types of bone tissue. By mimicking natural bone, it is hoped the implant material will better complement the natural regeneration process.

21 Jun 2011

Strawberries improve antioxidant capacity of blood

A group of volunteers ate half a kilo of strawberries every day for two weeks to demonstrate that eating this fruit improves the antioxidant capacity of blood. The study, carried out by Italian and Spanish researchers, showed that strawberries boost red blood cells' response to oxidative stress, an imbalance that is associated with various diseases.

21 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Ventana Medical receives FDA approval for new breast cancer genetic test

The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin, a commonly used breast cancer treatment.

15 Jun 2011